{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:27:07Z","timestamp":1790670427091,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2314-B-038-055-"],"award-info":[{"award-number":["MOST 109-2314-B-038-055-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["TMU108-AE1-B54"],"award-info":[{"award-number":["TMU108-AE1-B54"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013179","name":"Teh-Tzer Study Group for Human Medical Research Foundation of Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013179","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present a patient with refractory OCCC in whom conventional chemotherapy failed. Cachexia was induced by the disseminating recurrent tumors. Tumor tissue staining and genomic analysis revealed PD-L1 negativity, a low tumor burden, stable microsatellite instability, and two mutations in <jats:italic>ARID1A<\/jats:italic>. The patient was administered pembrolizumab combined with bevacizumab triweekly. Her serum CA-125 level decreased dramatically after the first cycle. A computerized tomography scan showed marked regression of the recurrent masses after 3\u2009cycles, and the patient reached complete remission after 9\u2009cycles. She showed good recovery from cachexia. We observed no marked side effects except for mild polyarthritis of the small joints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The therapeutic effect of checkpoint inhibitors combined with angiogenesis inhibitors is very promising in our patient with OCCC. Further clinical trials of tumors including <jats:italic>ARID1A<\/jats:italic> mutations are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-020-00751-3","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T17:04:40Z","timestamp":1607447080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report"],"prefix":"10.1186","volume":"13","author":[{"given":"Yu-Chien","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6967-8037","authenticated-orcid":false,"given":"Kuo-Chang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Lin","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phui-Ly","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Te","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cbpa.2020.02.005","volume":"56","author":"A Bellesoeur","year":"2020","unstructured":"Bellesoeur A, Torossian N, Amigorena S, Romano E. Advances in theranostic biomarkers for tumor immunotherapy. Curr Opin Chem Biol. 2020;56:79\u201390.","journal-title":"Curr Opin Chem Biol"},{"key":"751_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779\u201391.","journal-title":"Lancet Oncol"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M. \u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624\u201331.","journal-title":"Gynecol Oncol"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1758834012467661","volume":"5","author":"A Garcia","year":"2013","unstructured":"Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol. 2013;5:133\u201341.","journal-title":"Ther Adv Med Oncol"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12935-015-0267-0","volume":"15","author":"S Matsuzaki","year":"2015","unstructured":"Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki S, Kakuda M, Okazawa A, et al. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. Cancer Cell Int. 2015;15:117.","journal-title":"Cancer Cell Int"},{"key":"751_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30:1080.","journal-title":"Ann Oncol"},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/cas.14340","volume":"111","author":"S Nishio","year":"2020","unstructured":"Nishio S, Matsumoto K, Takehara K, Kawamura N, Hasegawa K, Takeshima N, et al. Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: subgroup analysis from the KEYNOTE-100. Cancer Sci. 2020;111:1324\u201332.","journal-title":"Cancer Sci"},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"e000438","DOI":"10.1136\/jitc-2019-000438","volume":"8","author":"R Okamura","year":"2020","unstructured":"Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1\/PD-L1 immunotherapy. J Immunother Cancer. 2020;8:e000438.","journal-title":"J Immunother Cancer"},{"key":"751_CR9","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2018.36.15_suppl.2006","volume":"36","author":"DA Reardon","year":"2018","unstructured":"Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, De Groot JF, et al. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol. 2018;36:2006.","journal-title":"J Clin Oncol"},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ygyno.2014.02.016","volume":"133","author":"PL Sung","year":"2014","unstructured":"Sung PL, Chang YH, Chao KC, Chuang CM. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol. 2014;133:147\u201354.","journal-title":"Gynecol Oncol"},{"key":"751_CR11","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731\u201341.","journal-title":"Lancet Oncol"},{"key":"751_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24:556\u201362.","journal-title":"Nat Med"},{"key":"751_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10147-020-01625-w","volume":"25","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, Takenaka M, Kawabata A, Yanaihara N, Okamoto A. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. Int J Clin Oncol. 2020;25:425\u201331.","journal-title":"Int J Clin Oncol"},{"key":"751_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/annurev-pathmechdis-012418-012917","volume":"15","author":"Y Wang","year":"2020","unstructured":"Wang Y, Hoang L, Ji JX, Huntsman DG. SWI\/SNF complex mutations in gynecologic cancers: molecular mechanisms and models. Annu Rev Pathol. 2020;15:467\u201392.","journal-title":"Annu Rev Pathol"},{"key":"751_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2019.04.056","volume":"154","author":"E Zsiros","year":"2019","unstructured":"Zsiros E, Frederick PJ, Akers SN, Attwood K, Wang K, Lele SB, et al. A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2019;154:23.","journal-title":"Gynecol Oncol"},{"key":"751_CR16","doi-asserted-by":"publisher","unstructured":"Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5945.","DOI":"10.1001\/jamaoncol.2020.5945"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00751-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-020-00751-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00751-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T17:13:51Z","timestamp":1607447631000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00751-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00751-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This case report was approved by the institutional review board of Shuang Ho Hospital (N201909048).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}